Cell & Gene: The Podcast
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
- Update frequency
- every 13 days
- Average duration
- 25 minutes
- Episodes
- 116
- Years Active
- 2021 - 2025
PepGen's SVP Head Of Clinical Development On Delivery Of Oligonucleotide Therapies
We love to hear from our listeners. Send us a message.
PepGen, a Cambridge, MA-based biotech, is advancing oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscu…
BridgeBio's Chief Regulatory Affairs Officer Adora Ndu on PDUFA VII Reauthorization
We love to hear from our listeners. Send us a message.
On the heels of Congress' reauthorization of the Prescription Drug User Fee Authorization (PDUFA) Act, BridgeBio's Chief Regulatory Affairs Offic…
Inside RNAi with Arrowhead Pharmaceuticals' Javier San Martin
We love to hear from our listeners. Send us a message.
Arrowhead Pharmaceuticals is a biopharmaceutical company based in Pasadena, CA that develops medicines that treat intractable diseases by silenci…
Planning For Manufacturing Capacity With Kite Pharma's Will Junker
We love to hear from our listeners. Send us a message.
Will Junker, Head of Manufacturing Quality at Kite Pharma, talks to Cell & Gene: The Podcast listeners about the challenges associated with capac…
Commercialization Learnings with Novartis Gene Therapies' President Chris Fox
We love to hear from our listeners. Send us a message.
With 20+ gene therapy targets in Novartis Gene Therapies’ pipeline, President Chris Fox and her team are hyper-focused on newborn screenings as t…
A Stem Cell-Derived Treatment for T1D
We love to hear from our listeners. Send us a message.
Sernova Corp. is a clinical-stage regenerative therapies company currently focused on insulin-dependent diabetes. CEO and President, Philip Tolei…
Best Practices for Partnering with a CDMO
We love to hear from our listeners. Send us a message.
Emily Moran, VP of Vector Manufacturing and Avi Nandi, VP of Process Development at the Center for Breakthrough Medicines share key consideration…
An Interview with Dr. Carl June
We love to hear from our listeners. Send us a message.
Dr. Carl June, an HIV gene therapy pioneer and the father of CAR-T cell therapy, joins Cell & Gene: The Podcast to discuss the current state of C…
Inside Gamma Delta T Cells with TC BioPharm’s CEO, Bryan Kobel
We love to hear from our listeners. Send us a message.
TC BioPharm's CEO Bryan Kobel explains gamma delta t cells (GDT) in depth as well as the advantages of using GDT cells as a cell therapy vehicle.…
Moving On from AAV with Poseida Therapeutics' CEO, Mark Gergen
We love to hear from our listeners. Send us a message.
Poseida Therapeutics is a broad platform technology company led by CEO, Mark Gergen. During this episode, Gergen explains how and why the company…
Inside the New Hybrid Roles for Cell Therapy Clinical Trials with Immatics' Michael Mehler
We love to hear from our listeners. Send us a message.
Autologous cell therapy clinical trials and products are very complex, and the stakeholder investment is diverse. Immatics' Director, Clinical Op…
Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu
We love to hear from our listeners. Send us a message.
Dr. Metin Kurtoglu, COO at Cartesian Therapeutics, explains the clinical-stage biotech's autologous RNA cell therapies, Descartes-08 for Myasthen…
Gene Therapy's Commercial Manufacturing Issues with Encoded Therapeutics' Andy Stober
We love to hear from our listeners. Send us a message.
Encoded Therapeutics' Chief Manufacturing Officer Andy Stober explains the unique commercial manufacturing issues in gene therapy and how to addr…
Inside CAR-T Therapy For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
We love to hear from our listeners. Send us a message.
Amit Kumar, Ph.D., President and CEO at Anixa Biosciences details the company’s progress on its Phase 1 trial for ovarian cancer. We also discuss…
Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris
We love to hear from our listeners. Send us a message.
Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a…
Rocket Pharmaceuticals' CEO Dr. Gaurav Shah on FDA's Clinical Holds on Gene Therapy Trials
We love to hear from our listeners. Send us a message.
Rocket Pharmaceuticals CEO Dr. Gaurav Shah offers his take on why gene therapy developers have been plagued by clinical holds, whether the FDA’s …
Inside Solid Tumor Therapies with BlueSphere Bio’s CEO Dr. David Apelian
We love to hear from our listeners. Send us a message.
BlueSphere Bio's CEO Dr. David Apelian explains the difficulties associated with treating solid tumor cancers as well as what the CGT sector need…
Restoration of Immune Balance with Anish Suri, Ph.D., President and CSO at Cue Biopharma
We love to hear from our listeners. Send us a message.
Cue Biopharma's Anish Suri, Ph.D., explains why the clinical-stage biopharma is engineering a novel class of injectable biologics to selectively …
REGENXBIO's Nina Hunter, Ph.D. Details the Accelerated Approval Pathway for Gene Therapies
We love to hear from our listeners. Send us a message.
REGENXBIO's VP of Regulatory and Science Policy, Nina Hunter, Ph.D., shares potential solutions to gene therapies' regulatory roadblocks and why …
Selecta Biosciences' Dr. Carsten Brunn on Gene Therapy with AAV Vectors
We love to hear from our listeners. Send us a message.
Selecta Biosciences' President and CEO Dr. Carsten Brunn details the company's ImmTOR platform, which can mitigate unwanted immune responses that…